Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Sang Gon Park"'
Autor:
Sung Hee Lim, Keun-Wook Lee, Jae-Joon Kim, Hyeon-Su Im, In-Ho Kim, Hye Sook Han, Dong-Hoe Koo, Jang Ho Cho, Chi Hoon Maeng, Min-Young Lee, Hyo Jin Lee, Jwa Hoon Kim, Sang Gon Park, Joo Young Jung, Seong-Hoon Shin, Ki Hyang Kim, Hyeyeong Kim, So Yeon Oh, Minsu Kang, Minkyu Jung, Sun Young Rha
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastri
Externí odkaz:
https://doaj.org/article/9274e12fab6e4e7e902af4a321c8f49d
Autor:
Cha Kyung Youn, Jung-Hee Lee, Gurusamy Hariharasudhan, Hong Beum Kim, Jeeho Kim, Sumi Lee, Sung-Chul Lim, Sang-Pil Yoon, Sang-Gon Park, In-Youb Chang, Ho Jin You
Publikováno v:
Cell Death and Disease, Vol 13, Iss 4, Pp 1-14 (2022)
Abstract The Hsp70-binding protein 1 (HspBP1) belongs to a family of co-chaperones that regulate Hsp70 activity and whose biological significance is not well understood. In the present study, we show that when HspBP1 is either knocked down or overexp
Externí odkaz:
https://doaj.org/article/1f269d88fbf34ffb9aa56c3ce717f04d
Publikováno v:
World Journal of Clinical Cases. 10:12268-12277
Autor:
Yong-sub Na, Sang-gon Park
Publikováno v:
Journal of Medical Case Reports, Vol 12, Iss 1, Pp 1-5 (2018)
Abstract Background Inflammatory myofibroblastic tumor is a rare benign neoplasm that frequently involves the lung and abdominopelvic region, and is found mainly in children and young adults. Inflammatory myofibroblastic tumor tends to be locally inv
Externí odkaz:
https://doaj.org/article/748c60cf0f7043168e17980de9781f02
Autor:
Junghoon Shin, Youngil Koh, Seo Hyun Yoon, Joo‐Youn Cho, Dae‐Young Kim, Kyoo‐Hyung Lee, Hyeong‐Joon Kim, Jae‐Sook Ahn, Yeo‐Kyeoung Kim, Jinny Park, Sang‐Kyun Sohn, Joon Ho Moon, Yoo Jin Lee, Seonghae Yoon, Jeong‐Ok Lee, June‐Won Cheong, Kyoung Ha Kim, Sung‐Hyun Kim, Hoon‐Gu Kim, Hawk Kim, Seung‐Hyun Nam, Young Rok Do, Sang‐Gon Park, Seong Kyu Park, Sung Hwa Bae, Hun Ho Song, Dong‐Yeop Shin, Doyeun Oh, Min Kyoung Kim, Chul Won Jung, Seonyang Park, Inho Kim
Publikováno v:
Cancer Medicine, Vol 7, Iss 5, Pp 1814-1823 (2018)
Abstract Although nilotinib has improved efficacy compared to imatinib, suboptimal response and intolerable adverse events (AEs) limit its effectiveness in many patients with chronic myeloid leukemia in chronic phase (CML‐CP). We investigated the 2
Externí odkaz:
https://doaj.org/article/d3afcb08b0d94b2f8771feee46de40c7
Publikováno v:
World Journal of Clinical Cases. 10:7899-7905
Autor:
Yong Sub Na1, Sang-Gon Park2 sgpark@chosun.ac.kr
Publikováno v:
American Journal of Case Reports. 2/3/2019, Vol. 20, p146-150. 5p.
Publikováno v:
World Journal of Clinical Cases
BACKGROUND Sjogren’s syndrome (SS), which affect salivary gland function, is an autoimmune disease. SS may involve extraglandular organs. Approximately 10 to 20 percent of SS patients have clinically significant lung disease, but presentation of pu
Publikováno v:
In Vivo
Background/Aim: Programmed cell death ligand 1 (PD-L1) is an immune checkpoint protein involved in immune evasion of malignant tumors. Confirmation of PD-L1 expression in non-small cell lung cancer (NSCLC) is necessary for the determination of immuno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d15e0309c39b9bc288a25f1cd42c0e8b
https://europepmc.org/articles/PMC9843772/
https://europepmc.org/articles/PMC9843772/
Autor:
In Gyu Hwang, Sang-Cheol Lee, Yaewon Yang, Sung Yong Oh, Sang-Gon Park, So Yeon Jeon, Dae Young Zang, Jung Hun Kang, Jun Ho Ji, Hyun Woo Lee, Woo Kyun Bae, Sun Jin Sym, Se-Il Go, Joung Soon Jang, Jung Hoon Kim
Publikováno v:
European Journal of Cancer. 157:21-30
Background The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFO